Zaglavara T, Haaverstad R, Cumberledge B, Irvine T, Karvounis H, Parharidis G, Louridas G, Kenny A
Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne, UK.
Heart. 2002 Apr;87(4):329-35. doi: 10.1136/heart.87.4.329.
To assess the accuracy of dobutamine stress echocardiography (DSE) and the optimal dose of dobutamine to detect myocardial viability in patients with ischaemic left ventricular (LV) dysfunction who are taking beta blockers, using the recovery of function six months artery revascularisation as the benchmark.
17 patients with ischaemic LV dysfunction (ejection fraction < 40%) and chronic treatment with beta blockers scheduled to undergo surgical revascularisation.
Regional cardiothoracic centre.
All patients underwent DSE one week before and resting echocardiography six months after revascularisation. A wall motion score was assigned to each segment for each dobutamine infusion stage, using the standard 16 segment model of the left ventricle. The accuracy of DSE to predict recovery of resting segmental function was calculated for low dose (5 and 10 microg/kg/min) and for a full protocol of dobutamine infusion (5 to 40 microg/kg/min).
Of the 272 segments studied, 158 (58%) were dysfunctional at rest, of which 79 (50%) improved at DSE and 74 (47%) recovered resting function after revascularisation. Analysis of results with a low dose showed a significantly lower sensitivity and negative predictive value than with a full protocol (47% v 81%, p < 0.001 and 65% v 82%, p < 0.05, respectively). The accuracy in the full protocol analysis was comparable with that reported in patients no longer taking beta blockers but was significantly lower than that in the low dose analysis (78% v 66%, p < 0.001).
Findings suggest that beta blocker withdrawal is not necessary before DSE when viability is the clinical information in question. However, a completed protocol with continuous image recording is required to detect the full extent of viability.
以血管重建术后六个月功能恢复情况为基准,评估多巴酚丁胺负荷超声心动图(DSE)检测服用β受体阻滞剂的缺血性左心室(LV)功能不全患者心肌存活性的准确性及多巴酚丁胺的最佳剂量。
17例缺血性LV功能不全(射血分数<40%)且长期接受β受体阻滞剂治疗、计划接受外科血管重建术的患者。
地区心胸中心。
所有患者在血管重建术前一周接受DSE检查,并在术后六个月接受静息超声心动图检查。使用左心室标准16节段模型,为每个多巴酚丁胺输注阶段的每个节段指定壁运动评分。计算低剂量(5和10微克/千克/分钟)和完整多巴酚丁胺输注方案(5至40微克/千克/分钟)时DSE预测静息节段功能恢复的准确性。
在研究的272个节段中,158个(58%)在静息时功能异常,其中79个(50%)在DSE时改善,74个(47%)在血管重建术后恢复静息功能。低剂量结果分析显示,其敏感性和阴性预测值显著低于完整方案(分别为47%对81%,p<0.001;65%对82%,p<0.05)。完整方案分析的准确性与不再服用β受体阻滞剂患者的报告结果相当,但显著低于低剂量分析(78%对66%,p<0.001)。
研究结果表明,当临床关注心肌存活性时,DSE检查前无需停用β受体阻滞剂。然而,需要完整方案并持续记录图像以检测心肌存活性的全貌。